QS Investors LLC Cuts Holdings in Pfizer Inc. (PFE)

QS Investors LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 831,314 shares of the biopharmaceutical company’s stock after selling 28,427 shares during the quarter. QS Investors LLC’s holdings in Pfizer were worth $27,924,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Shine Investment Advisory Services Inc. bought a new position in Pfizer in the second quarter valued at about $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer in the second quarter valued at about $103,000. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new stake in shares of Pfizer during the first quarter valued at about $121,000. Finally, Herndon Capital Management LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $120,000. 69.89% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently commented on the company. BMO Capital Markets set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research note on Friday. UBS set a $40.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. Deutsche Bank set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target on the stock in a research note on Thursday, November 23rd. Finally, Jefferies Group set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $38.77.

Shares of Pfizer Inc. (NYSE PFE) traded up $0.26 on Monday, reaching $36.00. The company’s stock had a trading volume of 2,102,077 shares, compared to its average volume of 19,939,289. Pfizer Inc. has a 12-month low of $30.90 and a 12-month high of $36.78. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market capitalization of $213,035.67, a price-to-earnings ratio of 14.30, a PEG ratio of 2.52 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.61 earnings per share. equities research analysts expect that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were issued a dividend of $0.32 per share. The ex-dividend date was Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.56%. Pfizer’s dividend payout ratio is 79.01%.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,280 shares of company stock valued at $2,118,988. Corporate insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/11/qs-investors-llc-cuts-holdings-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply